TIBCO Spotfire Extends Leadership Position in Life Sciences
Analytics Platform of Choice for Leading Pharmaceutical Companies Gains Momentum With Research and Clinical Product Innovation, Pharma-Focused Business Applications
TIBCO Software Inc. (NASDAQ: TIBX) today announced a strategic push to extend its leadership position in the global life sciences market with the release of several research and clinical analysis solutions, including Integromics Biomarker Discovery 2.0 for TIBCO Spotfire®, TIBCO Spotfire® Lead Discovery 2.0, TIBCO Spotfire® Pipeline Pilot Connector, and TIBCO Spotfire® Clinical Graphics 2.0. These solutions deliver integrated informatics and analysis, are central to research & development efforts in the life sciences industry and can transform the process of bringing life-saving medicines to market. Access to actionable knowledge early in the commercialization process of a new drug can lead to better safety outcomes for patients, and better regulatory and commercial outcomes for the industry.
The TIBCO Spotfire® Enterprise Analytics Platform is designed to become an essential tool for every decision maker in the pharmaceutical/biotech industry – from the scientist in the lab to the head of R&D. Timely and reliable access to essential scientific and operational data will drive informed decisions leading to better productivity. Data transparency enabled by the ability to integrate with the majority of current data sources further enhances the value of these corporate data assets and improves the quality of key decisions.
"Delivering novel medicines that serve the needs of patients and meet new, more stringent regulatory and reimbursement pressures is becoming increasingly difficult. Pharmaceutical and biotech companies are under increasing pressure to capitalize on all their data assets – from early Discovery and late stage Clinical Development to financial, logistical and operational data – to better enable the process of bringing new medicines to market that are safe, efficacious and effective," said Mark Lorion, vice president of Marketing, TIBCO Spotfire. "Spotfire has an outstanding track record of providing innovative analytics and visualization capabilities to the pharmaceutical and biotechnology industry globally and has deep domain expertise in this space."
Innovating Life Sciences Research Analysis
The introduction of Integromics Biomarker Discovery 2.0 for TIBCO Spotfire® sets a new standard for advanced methods for data access, normalization, pattern detection, treatment comparison, and functional analysis for scientists analyzing genomic expression data.
TIBCO Spotfire® Lead Discovery 2.0 allows chemists and biologists to quickly access chemical and biological data in a single analysis environment, then easily build best-practice applications for analyzing structure-activity relationships. With unparalleled data integration, one-step deployment, and summarized views for understanding new leads in context, the software offers intuitive visualizations and best practice analytics processes that any discovery team scientist can use to quickly ask and answer his or her own questions and drive better decisions.
The newly released TIBCO Spotfire® Pipeline Pilot Connector brings the power of Accelrys' Pipeline Pilot engine to the fingertips of every TIBCO Spotfire® user. Discovery scientists can now benefit from Pipeline Pilot's extensive chem- and bio-informatics toolkit to enrich the data available for interactive visual analysis in TIBCO Spotfire®, leading to more informed decisions in advancing discovery-phase projects.
TIBCO Spotfire is hosting a series of upcoming webcasts that profile these new solutions and feature customers, such as a leading Denmark-based pharmaceutical company, discussing how real-world scientists and researchers are gaining an edge with analytics. For complete information on the series, visit http://goto.spotfire.com/g/?YYM5SS96SH.
Speeding Clinical Trials and Development
The global focus on improving the safety of drugs will drive the need to identify and address safety issues as early as possible in the drug discovery and development process. Early attrition of unsuitable drug candidates can dramatically reduce costs and improve patient outcomes. With TIBCO Spotfire® Clinical Graphics 2.0, pharmaceutical organizations are now better equipped to communicate key pre-clinical and clinical information more effectively across the organization and to regulatory agencies, making important, real-time business decisions about their drug development candidates and strategies.
TIBCO Spotfire® Clinical Graphics 2.0 provides a palette of best-practice, statistical graphics for use in exploratory data analysis, clinical study reports, submission documents, presentations and journal articles. Enhanced visualizations – including tree maps, patient profile plots, and area bar charts – empower translational research by combining genomic, demographic, and safety data to enable new insights into safety, efficacy, and patient populations. Graphs can be created using a point-and-click interface, without the need for programming.
Three of the world's leading global pharmaceutical and biotech companies are among the Spotfire customers leveraging the TIBCO Spotfire platform to drive shorter development cycles and faster approvals of drugs that are safe and effective. Leading clinical data analysis experts from these companies outlined their methods on a complimentary Webcast that can be accessed and viewed at: http://spotfire.tibco.com/ContentCenter/Webcasts/04_22_2009.aspx.
Integromics Biomarker Discovery 2.0 for TIBCO Spotfire®, TIBCO Spotfire® Lead Discovery 2.0, TIBCO Spotfire® Pipeline Pilot Connector, and TIBCO Spotfire® Clinical Graphics 2.0 are available now. For more information visit: http://goto.spotfire.com/g/?YYM5SS96SH.
TIBCO Software Inc. (NASDAQ: TIBX) is a leading provider of enterprise analytics software for next generation business intelligence. TIBCO Spotfire products offer a visual and interactive experience that helps professionals quickly discover new and actionable insights in information. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value. Spotfire customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit http://spotfire.tibco.com.
TIBCO, TIBCO Software, Spotfire, TIBCO Spotfire Lead Discovery, TIBCO Spotfire Pipeline Pilot Connector, and TIBCO Spotfire Clinical Graphics are trademarks or registered trademarks of TIBCO Software Inc. or its subsidiaries in the United States and/or other countries. Integromics and Integromics Biomarker Discovery are registered trademarks of Integromics. All other product and company names and marks mentioned in this document are the property of their respective owners and are mentioned for identification purposes only.